Clinical Trial Will Explore First-Time Use of SurVaxM Vaccine in Combination with REVLIMID® to Treat Rare Blood Cancer
Immunotherapy Developed at Roswell Park Being Tested as Treatment for Multiple Myeloma BUFFALO, N.Y. — An immune-based therapy developed at Roswell Park Cancer Institute (RPCI) is moving forward with its…
Continue Reading Clinical Trial Will Explore First-Time Use of SurVaxM Vaccine in Combination with REVLIMID® to Treat Rare Blood Cancer